Trudell Medical Limited has reached an agreement to purchase the RDx business unit of Vyaire Medical.
RDx manufactures respiratory diagnostic products that are used in hospitals and private clinics worldwide and are trusted by specialists in the respiratory community.
The purchase is subject to court approval and is expected to close in 8-12 weeks. The acquisition will expand Trudell Medical’s already strong market position in aerosol drug delivery and lung health devices to include respiratory diagnostics.
Trudell Medical intends to operate RDx as a separate business unit and maintain operations in Germany and California.
The acquisition would ensure the continuation of service to RDx customers. Earlier this year, Vyaire Medical filed for Chapter 11 Protection and announced the company was focused on selling its business units to stable, well-capitalized buyers.
“We welcome the opportunity to add Vyaire RDx’s people, products, and passion to our Trudell Medical family. Respiratory diagnostics help to enhance and extend lives. This is in perfect alignment with our ‘Patient First’ core value across the Trudell Medical Group. Every day, we’re focused on designing and manufacturing products and services that improve patients’ lives,” Trudell Medical LimitedExecutive Chair George Baran said.
